-
Developing the next generation of treatments requires multinational co-operation and co-ordination. Bronchiectasis has historically been a neglected "Orphan" disease. An international network will build capacity to perform high impact clinical trials and observational studies in bronchiectasis
-
EMBARC is multidisciplinary, bringing bronchiectasis specialists together with basic scientists, microbiologists, physiotherapists, specialist nurses and patients. Developing new treatments for bronchiectasis will require a better understanding of the pathophysiology and natural history of the disease.
-
Sharing expertise and research protocols around Europe. Help to build a wider network and grow clinical research capacity for bronchiectasis in Europe.
-
The European Bronchiectasis Registry is currently recruiting- help us reach the target of 10,000 patients!
-
The European Bronchiectasis Registry is supported by the European Union Innovative Medicines Initiative under the "New Drugs for Bad Bugs" programme, to help facilitate the development of new antibiotics against Gram-negative infections
-
Advancing research and improving clinical care for patients with non-cystic fibrosis bronchiectasis
-
EMBARC promotes awareness and clinical excellence in bronchiectasis care through educational events, courses and online resources.
-
EMBARC works with the European Respiratory Society and the national societies and networks around the world to promote co-operation, data sharing and clinical research in bronchiectasis
-
EMBARC is a European Respiratory Society clinical research collaboration, dedicated to encouraging participation from young and experienced researchers around Europe in the field of bronchiectasis
EMBARC is a pan-European network committed to promoting clinical research and education in bronchiectasis, through sharing of protocols, research idea and expertise. Central to this project is the creation of the European Bronchiectasis Registry, a collaboration open to all investigators around Europe caring for patients with bronchiectasis.
Latest News
Take part in the new European NTM Registry
EMBARC is delighted to announce the launch of the new European Registry for Non-tuberculous Mycobacteria Pulmonary Disease (NTM-PD). The first meeting of the steering committee took place in Milan on …
Read MoreNew Bronchiectasis Guidelines
The new Bronchiectasis Guidelines will be released next week during the annual European Respiratory Society conference.
Join us on Sunday at 14:45 to hear more about the guidelines and have your …
Read MoreWBC2 Success
Congratulations to everyone involved in the organisation of the second World Bronchiectasis Conference in the beautiful setting of Milan. WBC has yet again proved another success with great …
Read MoreLatest Research
Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis
An update on the pharmacotherapeutic management of lower respiratory tract infections
The RESPIRE trials: Two phase III, randomised, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis
Recruitment
Join EMBARC
EMBARC is an open group and free to join.
For more information contact info@bronchiectasis.eu
Sign up at the registration page
| Talk to us on Twitter! |  |
| Connect with us on LinkedIn |  |
|
View video highlights here from the 1st World Bronchiectasis Conference, Hannover 2016#worldbronchiectasisconference |
 |
EMBARC AT ERS 2015
